Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
JW Pharmaceutical Corporation is a South Korean specialty and generic drug manufacturer focused on prescription pharmaceuticals, over-the-counter products, and contract manufacturing. The company operates domestic manufacturing facilities and generates revenue primarily from the Korean healthcare market, with exposure to pharmaceutical reimbursement pricing and generic competition dynamics. Strong ROE of 18.4% and low leverage (0.19 D/E) indicate efficient capital deployment in a mature pharmaceutical market.
JW Pharmaceutical generates revenue through pharmaceutical product sales under Korea's National Health Insurance reimbursement system, which provides pricing stability but limits margin expansion. The company benefits from established distribution relationships with Korean hospitals and pharmacies, regulatory barriers to entry for new competitors, and manufacturing scale advantages. Pricing power is constrained by government reimbursement schedules and generic competition, but the company maintains margins through manufacturing efficiency and product portfolio management across therapeutic categories.
Korean National Health Insurance reimbursement price adjustments - government-mandated pricing changes directly impact revenue and margins
New product launches and regulatory approvals - pipeline progression for specialty drugs or biosimilars drives growth expectations
Generic competition intensity - patent expirations and generic entry timing affect branded product revenues
Healthcare utilization trends in South Korea - demographic shifts and prescription volume changes
Won/USD exchange rate movements - impacts imported raw material costs and potential export revenues
Korean government healthcare cost containment initiatives - ongoing pressure to reduce pharmaceutical reimbursement prices to manage national healthcare budget, particularly for generic drugs
Biosimilar and generic competition intensification - patent cliffs and regulatory pathway improvements increase competitive pressure on branded products
Regulatory compliance costs - evolving quality standards and international harmonization requirements increase fixed cost burden for manufacturing operations
Market share erosion to larger multinational pharmaceutical companies with broader R&D pipelines and specialty drug portfolios
Domestic competition from other Korean generic manufacturers with similar cost structures and distribution access
Limited international diversification compared to global peers - concentrated exposure to Korean market dynamics and regulatory changes
High capex intensity ($28.1B against $79.4B operating cash flow) suggests ongoing facility investment requirements that could pressure free cash flow if revenue growth slows
Working capital management - pharmaceutical inventory and receivables from healthcare system require careful management to maintain liquidity
low - Pharmaceutical demand is relatively inelastic to economic cycles as prescription medications are essential healthcare products covered by Korea's universal healthcare system. However, discretionary OTC product sales show modest sensitivity to consumer spending patterns. The -5.2% net income decline despite 7.7% revenue growth suggests margin pressure from cost inflation or competitive dynamics rather than demand weakness.
Low direct sensitivity given minimal debt (0.19 D/E ratio) and strong cash generation ($79.4B operating cash flow). Rising rates have modest negative impact through higher discount rates applied to valuation multiples and potential pressure on healthcare system budgets. Korean monetary policy affects won-denominated financing costs, but the company's strong balance sheet minimizes refinancing risk.
Minimal - The company operates with low leverage and strong liquidity (1.51 current ratio), reducing dependence on credit markets. Healthcare reimbursement provides stable receivables, though government payment timing can affect working capital. Credit conditions primarily affect acquisition financing capacity rather than core operations.
value - The stock trades at 1.0x P/S and 7.7x EV/EBITDA with 9.8% FCF yield, suggesting value-oriented investors attracted to cash generation and reasonable valuation. The 18.4% ROE appeals to quality-focused value investors. Modest growth profile (7.7% revenue growth) and mature market position limit appeal to pure growth investors. Stable pharmaceutical demand provides defensive characteristics during economic uncertainty.
moderate - Pharmaceutical stocks typically exhibit lower volatility than broader market due to inelastic demand, but the stock's flat 1-year return (-0.8%) and modest recent performance suggest company-specific challenges. Korean market exposure and regulatory risk create episodic volatility around reimbursement decisions. Limited analyst coverage for Korean mid-cap pharmaceuticals may reduce liquidity and increase volatility during market stress.
